Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Bay-43-9006 scheduled to enter phase III in 2003

Nov. 20, 2002

FDA approves CMC amendment for ONYX-015

Nov. 20, 2002

Coley and GSK enter license agreement for cancer vaccines

Nov. 20, 2002

Kosan and NCI to clinically develop geldanamycin analogues

Nov. 20, 2002

ENMD-0995 trial for patients with multiple myeloma under way

Nov. 19, 2002

GC-C technology has potential as marker and target for gastric and esophageal cancers

Nov. 19, 2002

Helsinn grants CJ Corp. license and distribution rights for palonosetron in Korea

Nov. 19, 2002

New antiproliferative compounds isolated from fungal species

Nov. 19, 2002

Grant awarded for first clinical trial of squalamine in the treatment of prostate cancer

Nov. 18, 2002

Cell Therapeutics earns milestone payment

Nov. 18, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...